{"id":"sct510a","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Hematologic toxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SCT510A consists of engineered natural killer (NK) cells derived from healthy donors that have been modified to improve their ability to recognize and kill cancer cells. The therapy leverages NK cell cytotoxicity while potentially incorporating genetic modifications to enhance persistence, activation, and tumor-targeting capabilities. As an off-the-shelf cellular immunotherapy, it aims to provide a readily available treatment option for cancer patients.","oneSentence":"SCT510A is a genetically modified allogeneic natural killer cell therapy designed to enhance anti-tumor immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:33:47.095Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT05480293","phase":"PHASE3","title":"This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2023-02-14","conditions":"Wet Age-related Macular Degeneration","enrollment":446},{"nctId":"NCT04564937","phase":"PHASE1, PHASE2","title":"The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2020-11-06","conditions":"Wet Age-related Macular Degeneration","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SCT510A","genericName":"SCT510A","companyName":"Sinocelltech Ltd.","companyId":"sinocelltech-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SCT510A is a genetically modified allogeneic natural killer cell therapy designed to enhance anti-tumor immunity. Used for Hematologic malignancies (under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}